Argentina’s leading fertility program will deploy automated vitrification, standardized dish preparation robotics, and structured embryo assessment validation to reduce outcome variability, expand clinical capacity, and enhance patient reliability across its network.

Overture Life, the global leader in automated IVF and the first company to achieve live births from both robotic fertilization and robotic egg freezing, today announced the establishment of its first Center of Excellence for Automated Embryology in partnership with CEGYR, a flagship fertility program within the Eugin Group. Through this collaboration, CEGYR will implement Overture’s DaVitri automated vitrification platform across its clinical and egg-bank operations, adopt automated dish preparation systems to standardize complex laboratory workflows, and participate in the structured validation of Overture’s non-invasive embryo implantation assessment. Together, these capabilities will serve as a reference model for how large, multi-site fertility networks can deliver reproducible clinical performance at scale.

The initiative comes at a critical moment for reproductive medicine. IVF demand continues to rise internationally, driven by later family formation, expanding access to fertility benefits, and rapid growth in elective egg freezing. These trends have outpaced the availability of highly trained embryologists who perform the most intricate lab procedures under narrow time and temperature constraints. As a result, clinics around the world face outcome variability that is difficult to control solely through manual technique. By integrating automation directly into core embryology steps, networks are moving toward standardized, repeatable processes that support higher throughput and more predictable patient outcomes.

CEGYR brings decades of clinical leadership, scientific research, and high-volume operational experience to the partnership. The center performs thousands of IVF and egg-banking procedures each year and contributes to regional and international research programs. Its combination of scale, scientific oversight, and complex laboratory infrastructure positions it as an ideal proving ground for demonstrating how automated embryology can reduce cycle-to-cycle variability, improve workflow stability, and support teams under increasing patient demand. The Center of Excellence will generate real-world evidence to inform the integration of automated vitrification, standardized preparation protocols, and emerging non-invasive embryo-assessment technologies within regulated clinical environments.

“Access to consistent IVF outcomes should not depend on which embryologist is working on a given day,” said Hans Gangeskar, CEO of Overture Life. “By adopting automated vitrification and standardized preparation protocols, CEGYR is demonstrating how fertility networks can expand capacity while protecting clinical reliability. Their decision reflects a global shift toward system-level reproducibility, where outcomes are determined by validated processes rather than individual techniques.”

CEGYR’s involvement will accelerate both operational scale and scientific evaluation. The center will apply automated protocols across treatment cycles and its extensive egg bank while contributing structured, monitored data to Overture’s embryo-assessment validation program. These efforts will proceed within all applicable regulatory, ethical, and institutional frameworks, with data collection focused on linking automation to measurable improvements in laboratory consistency, embryo survival, and reproducibility across repeated cycles.

“At CEGYR, we see thousands of patients whose chances of success depend on both precision and consistency across every lab step,” said Dr. Sergio Papier, CEO and Medical Director of CEGYR. “As demand for fertility care grows, automation allows us to expand access without compromising clinical rigor. Partnering with Overture enables us to apply standardized protocols across our egg bank and embryology labs, giving every patient the same dependable quality while supporting our team with systems that reduce variability and strengthen outcomes.”

The collaboration also reflects a broader commercial and operational reality across global fertility networks. Increasing cycle volumes and staffing limitations are driving clinics to seek technologies that maintain results while relieving pressure on clinical teams.

“Clinics are seeking solutions that remove operational bottlenecks, minimize training demands, and free care teams to focus on patients rather than repetitive manual work,” said Matt Combs, Chief Commercial Officer at Overture Life. “CEGYR’s commitment shows that market-ready automation is now a differentiator for networks that expect growth. By integrating DaVitri and our automated prep systems across both clinical and egg-bank operations, they are building capacity that scales with demand rather than staff hours, enabling more families to start treatment sooner.”

While Overture’s DaVitri platform is already used across multiple regions and has demonstrated reproducible performance in early clinical evaluations, full integration and embryo-assessment validation will follow regulated, data-driven processes designed to support responsible adoption. The Center of Excellence will contribute prospective, real-world operational data that will help define best practices for automating high-precision embryology steps while maintaining the highest standards of clinical quality.

As additional fertility networks confront rising demand, constrained capacity, and increasing expectations for consistent results, the Overture–CEGYR Center of Excellence is expected to become a model for integrating automation into laboratory and egg-banking environments. Overture plans to work with leading programs across Europe, North America, and Latin America to establish a network of centers that apply standardized, validated workflows to improve reproducibility and expand access to reliable reproductive care worldwide.

For more information, you can visit www.cegyr.com.

About Overture Life

Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly egg freezing and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company’s DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture’s backers include Overwater Ventures, GV, Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility.

About CEGYR

CEGYR is one of the pioneering and most established centers in reproductive medicine in Argentina and the region. With more than four decades of experience, it combines scientific research, technological innovation, and a comprehensive approach to patient care. Its embryology laboratory is a benchmark in high-complexity procedures, cryopreservation, and gamete banking, performing almost 2000 cycles each year with a strong commitment to continuous, evidence-based improvement.

As part of the Eugin Group, CEGYR actively participates in international research networks and maintains quality standards aligned with the world’s leading scientific societies. Its laboratory infrastructure, the breadth of its training programs, and its operational capacity position it as an ideal center to integrate emerging technologies such as AI, automated laboratory systems, and non-invasive embryo analysis.

The incorporation of the Automated Embryology Center of Excellence reinforces its mission: to provide more precise, consistent, and accessible treatments, enhancing outcome reproducibility and expanding opportunities for more people to build a family with the support of experienced teams and validated processes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251215580752/en/